Fig. 1From: First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsMean plasma concentration of ASP3026, cycle 1, day 1. a Semi-log plot. b Linear plot. For patient numbers at each dose, refer to Tables 3 and 4 Back to article page